Your drug is our number one priority. We offer a range of devices and drug delivery technologies - developed through nearly 40 years of innovation - giving you flexibility to meet both your clinical and financial requirements. Our lab partners combine the facilities, methods and equipment you can count on to deliver scientifically validated data, with our staff’s deep knowledge of the regulatory process. So you can be sure your drug is optimally performing, and your submission plan is expertly designed.
Bringing an aerosol drug to market quickly and cost-effectively takes a successful combination of:
The aerosol delivery systems that Philips offers include features that ensure efficient aerosol drug delivery, in simple to use, portable devices. The devices below feature vibrating mesh technology.
Our scientists provide guidance for the ideal testing needed for clinical trials, regulatory submissions and approvals. Our laboratory capabilities include:
Our established team of scientists have vast experience and expertise in inhalation science, including aerosol testing, analytical, microbiology and regulatory requirements for device and drug submissions.
Our partner facilities are designed for testing, analytics and microbiology, and precisely controlled for temperature and humidity. We offer a comprehensive range of testing equipment, methods and measurements.
Our Partner feasibility testing process includes key steps to validate your drug and prepare it for regulatory submission.
Our advanced aerosol delivery products are the only home-use devices featuring Aerogen Vibronic® meshes*, the same unique palladium vibrating mesh technology used in hospital ventilators worldwide to deliver aerosolized medications. The central aperture plate is just 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the optimum particle size for deep lung penetration.
*excluding I-neb
Mesh devices should be considered as a first choice when looking at inhaled drug delivery. Devices with different modes of operation (active and passive vibrating mesh) are capable of delivering a variety of pharmaceutical formulations with a wide range of physichemical characteristics.
Presented by Philips Respironics at ERS, September 3rd-7th 2016. London UK
Meet Anna, a 7 -year old cystic fibrosis patient, who uses the Philips Respironics I-neb AAD system nebulizer to help manage her condition.
References 2 Nominal 0.5ml chamber delivered Salbutamol to filter in the range 534.1-591.5uL
1 Using 2.5ml Salbutamol
You are about to visit a Philips global content page
ContinueYou are about to visit the Philips USA website.
I understand